The FDA Blundered When It Approved Alzheimer Drug

The FDA has a difficult job. It is understaffed and underfunded. It has to walk a very fine line between prematurely approving a new drug that may turn out to be useless or even harmful and rejecting or delaying approval of a drug when earlier approval might have been saving lives. On the whole, I

Scroll to top